|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.36 USD | -1.82% |
|
+3.37% | -3.97% |
| Jul. 10 | Roivant Sciences Ltd. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04:20 PM | |
| Jul. 10 | AI Mania Masks Trade War Risks |  |
Company Valuation: Roivant Sciences Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 502.1 | 3,419 | 5,597 | 8,494 | 7,200 | 7,723 | - | - |
| Change | - | 580.9% | 63.72% | 51.75% | -15.23% | 7.26% | - | - |
| Enterprise Value (EV) 1 | 502.1 | 1,568 | 4,337 | 2,389 | 4,484 | 5,923 | 6,720 | 6,081 |
| Change | - | 212.38% | 176.49% | -44.92% | 87.75% | 32.09% | 13.46% | -9.52% |
| P/E ratio | -2.6x | -3.92x | -5.2x | 2.02x | -42x | -8.84x | -8.15x | -10.7x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0.4x | -0x | 0x | -0x | -0.96x | 0.5x |
| Capitalization / Revenue | - | 61.8x | 91.3x | 68.1x | 248x | 263x | 177x | 15.5x |
| EV / Revenue | - | 28.4x | 70.8x | 19.1x | 154x | 201x | 154x | 12.2x |
| EV / EBITDA | - | -1.17x | -3.75x | -2.2x | -4.5x | -4.33x | -5.15x | -8.58x |
| EV / EBIT | - | -1.16x | -3.69x | 0.56x | -4.47x | -5.28x | -5.65x | -6.84x |
| EV / FCF | - | - | -5.07x | -3.12x | -5.31x | -3.46x | -3.7x | - |
| FCF Yield | - | - | -19.7% | -32.1% | -18.8% | -28.9% | -27% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.76 | -1.26 | -1.42 | 5.23 | -0.24 | -1.285 | -1.394 | -1.063 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 55.29 | 61.28 | 124.8 | 29.05 | 29.42 | 43.54 | 499.5 |
| EBITDA 1 | - | -1,346 | -1,156 | -1,084 | -996.5 | -1,368 | -1,304 | -708.5 |
| EBIT 1 | - | -1,352 | -1,175 | 4,242 | -1,003 | -1,122 | -1,190 | -889.3 |
| Net income 1 | -809.2 | -845.3 | -1,009 | 4,349 | -172 | -872 | -988.6 | -745.5 |
| Net Debt 1 | - | -1,850 | -1,261 | -6,105 | -2,715 | -1,799 | -1,002 | -1,642 |
| Reference price 2 | 9.78 | 4.94 | 7.38 | 10.54 | 10.09 | 11.36 | 11.36 | 11.36 |
| Nbr of stocks (in thousands) | 51,340 | 692,072 | 758,427 | 805,846 | 713,549 | 679,806 | - | - |
| Announcement Date | 7/1/21 | 6/28/22 | 6/28/23 | 5/30/24 | 5/29/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -8.84x | 201.35x | -4.33x | -.--% | 7.72B | ||
| 37.3x | 12.31x | 28.09x | 0.75% | 712B | ||
| 15.04x | 4.2x | 11.56x | 3.34% | 378B | ||
| 27.26x | 6.59x | 13.78x | 3.42% | 340B | ||
| 16.85x | 6.08x | 12.14x | 3% | 305B | ||
| 14.15x | 3.48x | 8.6x | 3.84% | 259B | ||
| 17.15x | 4.63x | 11.21x | 3.26% | 237B | ||
| 22.3x | 4.15x | 12.2x | 2.28% | 219B | ||
| 10.68x | 3.46x | 7.48x | 3.86% | 209B | ||
| 22.58x | 5.78x | 11.22x | 3.25% | 159B | ||
| Average | 17.45x | 25.20x | 11.20x | 2.7% | 282.48B | |
| Weighted average by Cap. | 23.01x | 7.27x | 15.44x | 2.64% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ROIV Stock
- Valuation Roivant Sciences Ltd.
Select your edition
All financial news and data tailored to specific country editions
